The PE Ratio as of September 2024 (TTM) for iTeos Therapeutics, Inc. (ITOS) is -5.00

According to iTeos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.00. This represents a change of -33.94% compared to the average of -7.57 of the last 4 quarters.

iTeos Therapeutics, Inc. (ITOS) Historical PE Ratio (quarterly & annually)

How has ITOS PE Ratio performed in the past?

The mean historical PE Ratio of iTeos Therapeutics, Inc. over the last ten years is -9.58. The current -5.00 PE Ratio has changed 5.12% with respect to the historical average. Over the past ten years (40 quarters), ITOS's PE Ratio was at its highest in in the September 2022 quarter at 180.96. The PE Ratio was at its lowest in in the March 2020 quarter at -28.82.

iTeos Therapeutics, Inc. (ITOS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of iTeos Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

iTeos Therapeutics, Inc. (ITOS) Average PE Ratio

How has ITOS PE Ratio performed in the past?

The current PE Ratio of iTeos Therapeutics, Inc. (ITOS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

iTeos Therapeutics, Inc. (ITOS) PE Ratio vs. Peers

How is ITOS’s PE Ratio compared to its peers?

iTeos Therapeutics, Inc.’s PE Ratio is greater than Icosavax, Inc. (-8.27), greater than Mirati Therapeutics, Inc. (-5.32), greater than VectivBio Holding AG (-7.94), greater than Annexon, Inc. (-6.50), greater than Gracell Biotechnologies Inc. (-12.26), less than Theseus Pharmaceuticals, Inc. (-3.19), less than Monte Rosa Therapeutics, Inc. (-3.11), greater than Design Therapeutics, Inc. (-5.23), less than Erasca, Inc. (-3.94), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than TScan Therapeutics, Inc. (-6.03), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Acumen Pharmaceuticals, Inc. (-2.06), less than Amylyx Pharmaceuticals, Inc. (-0.97), greater than MoonLake Immunotherapeutics (-52.80), greater than Revolution Medicines, Inc. (-13.31), greater than Blueprint Medicines Corporation (-26.44), less than Sana Biotechnology, Inc. (-4.82), greater than Kymera Therapeutics, Inc. (-21.01),

Build a custom stock screener for iTeos Therapeutics, Inc. (ITOS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like iTeos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

iTeos Therapeutics, Inc. (ITOS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like iTeos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.